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Abstract
Genome-wide association studies (GWAS) have identified .500 common variants associated with quantitative metabolic
traits, but in aggregate such variants explain at most 20–30% of the heritable component of population variation in these
traits. To further investigate the impact of genotypic variation on metabolic traits, we conducted re-sequencing studies in
.6,000 members of a Finnish population cohort (The Northern Finland Birth Cohort of 1966 [NFBC]) and a type 2 diabetes
case-control sample (The Finland-United States Investigation of NIDDM Genetics [FUSION] study). By sequencing the coding
sequence and 59 and 39 untranslated regions of 78 genes at 17 GWAS loci associated with one or more of six metabolic traits
(serum levels of fasting HDL-C, LDL-C, total cholesterol, triglycerides, plasma glucose, and insulin), and conducting both
single-variant and gene-level association tests, we obtained a more complete understanding of phenotype-genotype
associations at eight of these loci. At all eight of these loci, the identification of new associations provides significant
evidence for multiple genetic signals to one or more phenotypes, and at two loci, in the genes ABCA1 and CETP, we found
significant gene-level evidence of association to non-synonymous variants with MAF,1%. Additionally, two potentially
deleterious variants that demonstrated significant associations (rs138726309, a missense variant in G6PC2, and rs28933094,
a missense variant in LIPC) were considerably more common in these Finnish samples than in European reference
populations, supporting our prior hypothesis that deleterious variants could attain high frequencies in this isolated
population, likely due to the effects of population bottlenecks. Our results highlight the value of large, well-phenotyped
samples for rare-variant association analysis, and the challenge of evaluating the phenotypic impact of such variants.
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Introduction
Genome-wide association studies (GWAS) based on common
single nucleotide polymorphisms (SNPs) have unequivocally
demonstrated the contribution of thousands of loci to risk for
common diseases and to variation in quantitative traits. However
for most such complex phenotypes, the variants identified to date
appear to explain only a fraction of heritable variation, suggesting
an important role for variants not assessed in GWAS. In
particular, the hypothesis that currently unidentified low-frequen-
cy genetic variants may have a major impact on complex
phenotypes has stimulated extensive efforts to discover such
variants through next-generation sequencing.
Over the next several years it will increasingly become feasible
to conduct comprehensive variant discovery through exome or
whole genome re-sequencing studies. Such studies have the
potential to demonstrate the impact on complex phenotypes of
genes, pathways, and networks that GWAS have not yet
implicated in these phenotypes. However it is increasingly clear
that identifying associations at genome-wide or exome-wide
thresholds of statistical significance will require large samples,
and thus these experiments remain very costly. Although targeted
re-sequencing studies of large samples do not provide the same
likelihood of implicating novel genes as do genome-wide or
exome-wide sequencing, they offer an excellent opportunity to
obtain an initial picture of the relative phenotypic impact of
variants across the complete allele frequency spectrum, in regions
of interest. Such studies require evaluation of a relatively limited
number of variants and, if prior evidence indicates that variants
within the targeted region contribute to the phenotype, require a
less stringent statistical threshold.
Genes within loci for which GWAS have shown significant
associations represent logical foci for investigations across the
allelic frequency spectrum. Several genes are now known to
harbor both rare variants responsible for Mendelian disorders and
common variants associated with related phenotypes [1,2].
Resequencing of such genes may suggest particular variants as
contributors to the GWAS signal, and may identify variants whose
association with the phenotype is independent of the GWAS
signal. Together, such variants provide starting points to
investigate the heritable component of biological processes
underlying the associated phenotypes.
We therefore undertook a re-sequencing study of Finnish
cohorts, targeting loci identified from GWAS of quantitative
metabolic traits, including: fasting blood levels of lipids and
lipoproteins (triglycerides, TG; high-density lipoprotein cholester-
ol, HDL-C; low-density lipoprotein cholesterol, LDL-C; and total
cholesterol, TC), glucose (FG), and insulin (FI). Several of these
traits (TG, HDL-C, and FG) are components of the metabolic
syndrome, an aggregation of variables that increase risk for type 2
diabetes (T2D) and cardiovascular diseases [3]. We report here the
results of such targeted re-sequencing of.6,000 individuals drawn
from a population cohort (the 1966 Northern Finland Birth
Cohort, NFBC; [4]) and a T2D case-control sample (the Finland-
United States Investigation of NIDDM Genetics study, FUSION;
[5,6], which included 919 individuals with T2D and 919 normal
glucose-tolerant controls). In these individuals, we sequenced the
coding regions of 78 genes selected from 17 loci that showed
genome-wide significant association to one or more of the
designated quantitative metabolic traits in GWAS meta-analyses
that included these studies [7,8]. Details on how we selected loci
and genes within loci for re-sequencing can be found in Text S1.
We focused on these Finnish cohorts for two reasons, both of
which concern the relationships expected between population
history and the distribution of rare variants within a study sample.
First, when a founder population has expanded recently from
severe bottlenecks, as in Finland, many variants may disappear
from the population while others increase rapidly in frequency
owing to subsampling and genetic drift. Thus, while the overall
number of rare variant sites observed in sequencing studies of the
Finnish population is smaller than in other European populations
[9], some deleterious variants are observed at a much higher
frequency in Finland than in other populations. These variants
include the mutations responsible for about 40 rare Mendelian
disorders, the so-called ‘‘Finnish disease heritage’’ [10,11]. We
hypothesized that some variants with a large effect on quantitative
metabolic phenotypes would also have attained a relatively high
frequency in the Finnish population, so that by re-sequencing
Finnish samples we could identify novel associations that might be
unfeasible to detect in comparably sized samples from most other
populations.
Second, the availability of information specifying the birthplace
of most members of the NFBC and FUSION cohorts (or their
parents) addresses the recently raised concern that unidentified
population substructure may pose a particular issue in association
analyses of rare variants (e.g. those with frequency ,1%) [12].
This concern reflects the expectation that such variants have
generally arisen more recently than common variants and are
therefore more likely to differ in frequency between study
populations; this concern is mainly relevant in studies where the
geographical origin of the subjects is unknown [12]. Indeed,
previous studies in Finnish samples (including NFBC) have shown
that the available birthplace data provide a highly accurate
delineation of population substructure [7,10].
Results
Characteristics of study cohorts and re-sequencing
summary statistics
Principal components analysis (PCA) using 122 k SNPs typed
on genome-wide arrays revealed that the NFBC and FUSION
samples overlap broadly in the first two PC dimensions (Figure
Author Summary
Abnormal serum levels of various metabolites, including
measures relevant to cholesterol, other fats, and sugars,
are known to be risk factors for cardiovascular disease and
type 2 diabetes. Identification of the genes that play a role
in generating such abnormalities could advance the
development of new treatment and prevention strategies
for these disorders. Investigations of common genetic
variants carried out in large sets of research subjects have
successfully pinpointed such genes within many regions of
the human genome. However, these studies often have
not led to the identification of the specific genetic
variations affecting metabolic traits. To attempt to detect
such causal variations, we sequenced genes in 17 genomic
regions implicated in metabolic traits in .6,000 people
from Finland. By conducting statistical analyses relating
specific variations (individually and grouped by gene) to
the measures for these metabolic traits observed in the
study subjects, we added to our understanding of how
genotypes affect these traits. Our findings support a long-
held hypothesis that the unique history of the Finnish
population provides important advantages for analyzing
the relationship between genetic variations and biomed-
ically important traits.
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S1). Phenotype distributions also overlap considerably between the
cohorts (Table S1), and comparison of mean residual values after
regressing the combined sample on age, age2, and sex showed no
significant differences between NFBC and FUSION for any
phenotype (p.0.77 for all comparisons; see Text S1), after
excluding T2D cases from analysis of FG and FI.
We selected for re-sequencing the protein-coding regions and 59
and 39 untranslated regions (UTRs) of the genes within 17 loci that
had previously demonstrated significant association (p,561028)
in GWAS to one or more metabolic phenotype (Table 1); TG
(eight loci), HDL-C (nine loci), LDL-C (six loci), TC (nine loci), FG
(six loci), and FI (one locus) [7,8,13–15]. The selection of the loci
depended on the evidence from meta-analyses of several
independent studies, but for eight of them, NFBC alone showed
genome-wide significant association to one or more of the six
phenotypes. We defined loci as the regions bracketed by the
nearest recombination hotspots (.10 cM/Mb) on both sides of the
reported GWAS SNPs. The numbers of genes included in the
GWAS loci so defined ranged from one (four loci) to 50 (the
MADD locus). As we did not have the resources to sequence all
possible genes at each locus, we sequenced the genes nearest to the
SNPs that showed genome-wide significant association with these
phenotypes (see Text S1 for more detail), for a total of ,270 kb of
sequence.
We conducted targeted Illumina sequencing using 150 bp
probes designed to capture primarily coding sequence, in whole-
genome amplified (WGA) DNA from 6,958 individuals; 6,123 of
these individuals (4,447 NFBC, 836 FUSION normal glucose
tolerant controls, and 840 FUSION T2D cases) passed quality
control procedures (Text S1). Mean depth of coverage (per bp per
person) per gene ranged from 316–2856 (Table S2, Figure S2,
and Text S1). On average, 96% of sequenced base pairs within a
gene had genotype quality score $50 in $75% of subjects; some
genes were covered at this level for as few as 60% of base pairs
(Table S2). After this initial quality control process, we identified
2,221 variant sites, 1,779 (80%) with MAF,1%.
Validation of rare variants
It is difficult to distinguish between low count variants and
sequencing artifacts, and we reasoned that such artifacts might be
increased in our study given that all DNAs had been whole-
genome amplified (WGA). We therefore attempted to validate low
count variants by PCR-amplification of the putative variant site in
genomic DNA from variant carriers (or WGA DNA if genomic
DNA was not available) and sequencing using a different platform
(Roche 454 FLX). We sequenced all variants identified in #3
individuals in our sample and not reported in dbSNP version 135
(N= 1,104, Text S1), and considered validation for the sites as (1)
their being variable and (2) the specific non-reference genotypes
being correct as called.
Overall, we validated 89.5% of these 1,104 sites including 100%
of the 91 sites with variants present three times and 271 of 273
(99.3%) corresponding non-reference genotypes; 205 of 207
(99.5%) of the 207 sites with variants present twice and 397 of
414 (95.9%) corresponding non-reference genotypes. Among
singletons, we validated 691 of 806 (85.7%) non-reference
genotypes; however, 336 of these validated only in WGA DNA
(the only DNA source available for these samples). Conservatively,
we excluded from further analyses these 336 WGA-only singleton
sites, along with 104 singleton sites that were refuted (49 sites), not
covered (20 sites), or found to be WGA artifacts (35 sites). Eleven
additional singleton sites were found to be homozygous alternative
when validated, bringing the number of retained singleton sites to
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366 and the total number of retained sites (among the 1,104 for
which validation was attempted) to 663.
After validation, we included a total of 1,780 variable sites for
further analysis. The subsequently released dbSNP version 137
included 76 of our non-validated sites: our experiments had
directly refuted four of these sites, we had not adequately covered
five of them, and we had validated 67 sites only in WGA DNA.
We re-included the 72 non-refuted sites, bringing the total number
of validated polymorphic sites for subsequent analysis to 1,852
(Table S3).
To quantify the increase in rare variation information provided
by sequencing compared with genotyping, we calculated the
overlap between variants found in this study and those observed in
a larger Finnish sample: 9,660 Finnish participants from the
population-based Metabolic Syndrome in Men (METSIM) study
[16] who were genotyped with the Illumina ExomeChip. The
ExomeChip captured only 346 (19%) of the 1,852 polymorphic
sites that we identified through sequencing.
Characteristics of sequence variants
The majority of sequence variants (1,114, 60%) were in coding
sequence (37% non-synonymous [NS] and 23% synonymous)
while 738 (40%) were in introns or UTRs (Figure S3). PolyPhen2
[17] predicted 236 variants to have a deleterious impact: 213
missense ‘‘probably damaging’’ and 23 nonsense variants. Of these
236 variants, 21 (19 missense and two nonsense) were present in
homozygous form in at least one individual. For all 21 of these
variants, the phenotype distributions for rare-allele homozygotes
overlapped with the phenotype distributions of the common-allele
homozygotes (Figure S4), suggesting these variants are not
sufficient to cause extreme phenotypes. A total of 1,410 of the
1,852 validated variants (76%) had MAF,1%, including 486
(26%) singleton and 217 (12%) doubleton variants (Figure S5).
Nucleotide diversity, as estimated by Watterson’s measure
hW=7.1610
24 was larger than the pair wise heterozygosity
estimator hp=3.5610
24, reflecting the abundance of singleton
sites.
We observed less overall variation than that seen in earlier
sequencing studies of individuals of European descent; one variant
site in every 147 bp sequenced, as compared to every 21 bp [9],
57 bp [18] or 83 bp [19]. While the sample size in the study of
Nelson et al. [9] was larger (12,514 European Americans) than that
of our study, the sample sizes in Tennessen et al. [19] and Fu et al.
[18] were smaller (1,351 and 4,298 European Americans,
respectively; note that the samples sequenced in the latter two
studies represented two different data releases from the same
dataset). Nelson et al. observed that in the Finnish samples in their
study, the number of variant sites per kb of sequence, was about
one-third that of similar sized samples from southern Europe.
Thus, while differences in sequencing coverage and in the number
of sequencing artifacts could partially account for our observation
of reduced numbers of variant sites compared to other studies, the
results of Nelson et al. suggest that the Finnish population
bottleneck may have played a larger role.
The reduced variation observed in our study compared to the
three previous studies, primarily reflects numbers of rare variants.
Nelson et al. report that 95% of their variant sites were rare
(MAF,0.5%), with 74% seen in only one or two copies. Similarly,
Tennessen et al. report that 72% of variant sites were seen in #3
copies. In our study, by contrast, 72% of variants were rare, 38%
were seen in one or two copies, and 44% were seen in #3 copies.
By down-sampling our data [20] to match the sample sizes of
Tennessen et al. and Fu et al., and down sampling the data of
Nelson et al. to match our sample size, we directly compared our
site-frequency spectra (SFS) with those observed in these three
studies. We caution against over-interpretation of these SFS, as
they can be impacted by differences between studies in the choice
of genes sequenced, variant ascertainment, and coverage. Never-
theless, in our sample, a substantially lower percentage of coding
variants have MAF,1% than in any of the other three studies
(Table S4). Conversely, in our sample we observe a higher
proportion of so called ‘‘Goldilocks alleles’’: variants with MAF
0.5–2%, a frequency sufficient for single-variant analyses of
potentially large-effect variants [21]. For example, while Nelson
et al. report that 1.1% of NS variants are Goldilocks alleles, we
observe that 7.4% of NS variants fall in this frequency range.
While we observe fewer rare variants than these other
sequencing studies, the proportion of NS variants among rare
coding variants in our study (65%; 95% CI= 62%–68%) is similar
to that seen in Nelson et al. (63%). The proportion of rare variants
predicted to be functional is also roughly similar between our study
and other studies. For example, Tennessen et al. report that almost
96% of SNVs predicted to be functional have MAF,0.5%, and
state an odds ratio of 4.2 that such rare variants are functional
compared to variants with MAF.0.5%. We find that 89% of
SNVs predicted to be functional are rare, and estimate an odds
ratio of 3 (95% CI= 1.98–4.52).
Phenotype associations
A total of 39 unique locus-phenotype combinations represent
the previously reported associations between the 17 re-sequenced
loci and one or more of the six metabolic phenotypes: 32
associations for lipid measures, six for fasting glucose, and one for
insulin (Table 1). To follow up these previous findings, we
conducted association tests on the combined NFBC/FUSION
data (see Methods). We conducted single-variant tests (regression
of phenotype residuals on an additively coded genotype, see
Methods) to assess association in each of the 39 locus-phenotype
sets for all validated variants with MAF.0.1%; tests under
alternative genetic models did not reveal any additional association
evidence. Since multiple independent association signals may be
present at a locus, we evaluated the relation of each newly
associated variant to the ‘‘array SNP,’’ the SNP genotyped in the
combined NFBC/FUSION sample with smallest p-value in this
sample in single-SNP association tests (Table 1). We then
conducted single-variant analyses conditional on the array SNP,
by including the array SNP genotype as a covariate in the linear
regression.
We used gene-level tests to evaluate the collective impact of
non-synonymous (NS) variants with MAF,1% for each of the 62
genes that harbored at least two such validated variants,
considering only phenotypes that showed prior evidence of
association to the locus (a total of 147 tests). We adopted this
MAF threshold after determining that any higher MAF threshold
simply recapitulated associations identified by the single-variant
tests. Given different alternative models of interest, we performed
two minimally correlated tests: CMC [22] which assumes the
direction of effect for all rare variants is the same, and SKAT [23]
which is better tuned to the setting in which the direction of effect
of rare variants is mixed.
Taking the combined results from our single-variant and gene-
level analyses, we evaluated to what degree re-sequencing of these
17 loci has advanced our understanding, beyond what was known
from GWAS, of the phenotypic impact of genetic variation. We
considered such an advancement to consist of either identification
of additional, independent association signals, or the detection of
association to rare variants.
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For several of the lipid-associated loci, we were able to assess the
evidence for multiple independent signals in relation to a similar
analysis conducted on SNP data by Teslovich et al. 2010 [8]. This
comparison has two limitations: our study and that of Teslovich et
al. did not examine the same set of variants, and for five of the 13
lipid loci, our variant set did not contain a good proxy (r2.0.8) for
the lead SNP of Teslovich et al. To counter these limitations, we
used information imputed from NFBC data on pairwise LD
between variants analyzed in the two studies, and assumed that
any pair of variants with r2,0.2 in NFBC were effectively
independent.
We used here a significance threshold of p,0.001 (approxi-
mately the cutoff obtained by applying the Benjamini-Hochberg
[24] rule to control FDR at the 0.02 level across all the variants/
genes and phenotypes tested, see Methods). For 27 of the 39
locus-phenotype combinations, the re-sequencing analysis essen-
tially recapitulated the results from the GWAS. For the remaining
12 locus-phenotype combinations (at seven loci), we summarize
below how re-sequencing has advanced our understanding of
genotype-phenotype relationships; MAF, p-values, and annota-
tions for all associated variants at these seven loci are presented in
Table 2.
ABCG8 locus (LDL-C). In re-sequencing seven genes at this
locus, we identified 231 validated variants, and detected associ-
ation independent of the array SNP with variant rs145756111 in
the ABCG8 gene (Figure S6AB, Table 2, p= 6.161024). Compar-
ison with the data of Teslovich et al. indicates three distinct LDL-C
signals at this locus: (1) a single signal given by our array SNP and
the Teslovich et al. lead SNP (r2 = 0.98); (2) the second common
signal identified by Teslovich et al. (rs4953023); and (3) the rare
variant signal identified here (rs145756111), which is independent
of both common signals.
G6PC2 locus (FG). Table 2, p= 2.661026). The independent
associated SNP rs138726309 codes for a missense variant
(His177Tyr) predicted to be ‘‘probably damaging’’ by PolyPhen2
[17], occurring at a highly conserved site; the reference amino acid
is observed at 25 of 26 aligned homologous proteins, refSeq
NP_066999, SwissProt Q9NQR9. This SNP is a candidate causal
variant and a priority for follow-up investigations; it is also
significantly increased in frequency in Finland compared to other
European populations (MAF=0.014 in Finland vs MAF=0.0023
in the European ancestry samples in the Exome Variant Server,
http://evs.gs.washington.edu/EVS/, p,10216).
LPL locus (HDL-C, TG). We re-sequenced only LPL at this
locus, detecting 43 validated variants, including a nonsense
variant, rs328, in strong LD with the array SNP. We identified
a second variant, rs268, in low LD (r2 = 0.002) with rs328 and
associated with both HDL-C and TG (Figure S6E–H, Table 2,
HDL-C p= 2.261027, TG p= 9.361025). Comparison with the
data of Teslovich et al. indicates three distinct signals at this locus
for both HDL-C and TG: (1) a signal given by our array SNP and
the Teslovich et al. lead SNP (r2 = 0.87); (2) the second signal
reported by Teslovich et al. at rs7016529; and (3) the rare variant
identified by sequencing, rs268.
ABCA1 locus (HDL-C, TC). We identified 73 validated
variants in ABCA1, the only gene we sequenced in this region. Two
sequence variants with single SNP associations to HDL-C are
independent of the array SNP at this locus (Figure S6IJ, Table 2,
variants rs2066718, p = 9.361025, and rs2066715, p = 5.161024,
pair wise r2 = 0.000). Comparison with the data of Teslovich et al.
suggests four HDL-C signals at this locus; our array SNP is
modestly correlated with their lead SNP (r2 = 0.62), and poorly
correlated with their independent signal at SNP rs11789603
(r2 = 0.17), and sequence variants rs2066718 and rs2066715 are
not correlated to either of the common SNPs (r2,0.01 for all pair
wise comparisons).
The gene-level tests used 23 ABCA1 variants, eight not
previously reported (as of dbSNP 137), one nonsense variant
and seven missense variants, all predicted to be ‘‘probably
damaging’’ (Table S3). These tests implicated rare ABCA1 variants
in both TC and HDL-C (TC: CMC p=3.761025, HDL-C:
CMC p=5.061024). For TC, 18 of the 23 variant sites (with 138
of the 157 minor alleles) are associated with lower TC (Figure 1);
16 of these 23 variants were also associated with decreased HDL-
C, based on single-marker tests. The observation that most
variants have the same direction of effect is consistent with
stronger association evidence for CMC than for SKAT (TC:
SKAT p=0.018, HDL-C: SKAT p=0.0033; Table S5).
We attempted to determine whether any single rare variant
could be responsible for the gene-level test signal at this locus, and,
if so, whether its contribution could be separated from that of the
more common variants assessed in the single-variant tests. For this
purpose we used all of the non-singleton sequence variants
detected in ABCA1 to construct a multivariate linear model with
HDL-C as a response variable. We employed stepwise regression
analysis, using the Bayesian Information Criteria (BIC) criterion to
select the best model (see Methods). That model (Table 3) includes
six variants: the array SNP, the two independent common variants
identified in the single-variant analyses (rs2066718 and
rs2066715), and three rare variants (MAF=0.00025, 0.00049,
0.00015), one of which (chr9:107548661) is predicted by
PolyPhen2 to be a ‘‘probably deleterious’’ missense variant.
Inclusion of all sequence variants along with the array SNP in a
model to predict HDL-C increases the HDL-C variance explained
to 1.8%, compared to 0.62% when HDL-C is modeled by the
array SNP alone. Our results underscore the distinct contributions
to HDL-C variation of both common and rare variants at this
locus.
APOA1 locus (HDL-C, LDL-C, TC, TG). We re-sequenced
four genes in this region, discovering 55 variants, and gained
additional understanding of the impact of this locus on LDL-C,
TC, and TG. For TG, variants rs3135506 (p = 6.961028) and
rs2266788 (p = 7.7610213) demonstrate associations that are
independent of each other, although neither is clearly independent
of the array SNP (Figure S6KL, Table 2). For LDL-C and TC,
variant rs651821 also shows association independent of the array
SNP (Figure S6M–P, Table 2, p = 2.261024 and p=9.361025,
respectively). Comparison with Teslovich et al. suggests three
distinct TC signals at this locus; while rs651821 shows modest
correlation with their lead SNP (r2 = 0.56), our array SNP displays
little correlation with two independent signals that they identified
(r2#0.1).
LIPC locus (HDL-C, TG, TC). We identified 27 variants in
re-sequencing LIPC, the only gene in this region, and detected
association, independent of the array SNP, to HDL-C and TG
(Figure S6Q–T, Table 2, p = 7.061028 and 2.761025, respec-
tively). This independent signal is from rs28933094, a missense
variant predicted to be ‘‘probably damaging,’’ that in recessive
form causes hepatic lipase deficiency [25]. This variant is found at
a higher frequency in Finland (MAF=0.015) than in other
European populations (MAF=0.0019 among the European
Ancestry samples in the Exome Variant Server, p,10216).
Comparison with Teslovich et al. suggests three independent
associations for both HDL-C and TG at this locus. For HDL-C,
our array SNP, rs1532085, is the lead SNP reported by Teslovich
et al. and shows low LD (r2 = 0.004) with variant rs28933094 or
with an independent signal reported by Teslovich et al.
(rs2070895). For TG, our array SNP, rs261336, is modestly
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correlated with the independent signal (rs261334) reported by
Teslovich et al. (r2 = 0.57); however, our variant rs28933094 is not
correlated (r2 = 0.004) with Teslovich et al. lead SNP, rs1532085.
CETP locus (HDL-C, LDL-C, TG, TC). We re-sequenced
five genes in this region, identifying 148 variants, and detected
HDL-C association that is independent of the array SNP to
variant rs5880 (Figure S6UV, Table 2, p = 3.961025). Compar-
ison with the data of Teslovich et al. suggests three distinct HDL-C
associations at this locus; our array SNP, rs3764261, is identical to
their lead SNP; however, they identified an independent signal at
SNP rs9939224 that is not well correlated with rs5880 (r2 = 0.07).
Gene-level analyses at this locus used 65 variants in 5 genes and
highlighted the contribution to HDL-C of rare variants in CETP,
including four missense variants predicted to be ‘‘probably
damaging’’, two of which were not in dbSNP 137 (Table S3)
(SKAT p=6.461024, Table S5, Figure 2). The fact that four of
the eight NS variants in CETP were associated with increased
HDL-C and four with decreased HDL-C explains the stronger
association evidence with SKAT than with CMC. For other
phenotypes, it is not clear that re-sequencing substantially
advanced our understanding of the role of this locus. A
multivariate linear model (Table 4) for CETP selects four variants
for HDL-C response: the array SNP, two common variants
(rs5880 and rs5883), and a rare variant (rs2303790, a missense
variant predicted by PolyPhen2 to be ‘‘probably deleterious’’). The
array SNP alone accounts for 3.3% of variance in HDL-C; by
adding the sequence variants to the model the proportion of HDL-
C variability explained increases to 4.1%, underscoring the distinct
contributions to HDL-C variation made by both common and
rare variants in this gene.
We also carried out a T2D case-control analysis by comparing
FUSION T2D cases to the combination of NFBC participants and
FUSION controls. The first five PCs were included as covariates
to control for stratification. Single-variant analyses conducted for
the 442 SNPs with MAF.1% revealed no significant associations
to T2D, using either the standard definition of genome-wide
Table 2. Loci with multiple independent single-variant association signals to SNPs with MAF.0.1%.
Trait/Locus1 Gene Variant MAF Allele Type Beta2 P-value3
PV array
SNP only4
PV array
SNP+sequence
variants5
LDL-C in ABCG8 rs6756629 .090 A array SNP 20.15 1.3E-05
ABCG8 rs145756111 .011 A synonymous 0.31 6.1E-04 1.2% 1.4%
FG in G6PC2 rs560887 .310 A array SNP 20.15 9.0E-12
G6PC2 rs138726309 .014 T missense probably
damaging
20.41 2.6E-06 1.2% 1.7%
HDL-C in LPL rs10096633 .100 A array SNP 0.15 6.8E-06
LPL rs268 .018 G missense benign 20.38 2.2E-07 0.72% 1.2%
TG in LPL rs10096633 .100 A array SNP 20.19 1.9E-08
LPL rs268 .018 G missense benign 0.31 9.2E-05 0.59% 0.85%
HDL-C in ABCA1 rs2575875 .300 A array SNP 20.08 8.4E-05
ABCA1 rs2066718 .015 T missense benign 0.32 9.3E-05
ABCA1 rs2066715 .055 T missense benign 0.15 5.1E-04 0.62% 1.1%
TG in APOA1 rs12805061 .270 G array SNP 0.004 .86
APOA5 rs2266788 .089 G 39-UTR 0.27 7.7E-13
APOA5 rs3135506 .059 C coding-synonymous 0.24 6.9E-08 0.4% 1.6%
LDL-C in APOA1 rs11216267 .460 G array SNP 0.08 2.3E-05
APOA5 rs651821 .085 C 59-UTR 0.13 2.2E-04 1.4% 1.6%
TC in APOA1 rs11216267 .460 G array SNP 0.08 1.3E-04
APOA5 rs651821 .085 C 59-UTR 0.14 9.3E-05 1.1% 1.4%
HDL-C in LIPC rs1532085 .440 A array SNP 0.13 9.4E-12
LIPC rs28933094 .016 T missense probably
damaging
0.42 7.0E-08 1.2% 1.8%
TG in LIPC rs261336 .230 G array SNP 0.09 1.4E-04
LIPC rs28933094 .016 T missense probably
damaging
0.33 2.7E-05 0.2% 0.5%
HDL-C in CETP rs3764261 .270 A array SNP 0.27 1.6E-40
CETP rs5880 .024 C missense probably
damaging
20.26 1.8E-05 3.3% 3.6%
1FG and TG were LN transformed prior to analysis; the regression coefficient is on the LN scale.
2Beta is the estimate of the regression coefficient, and provides the amount and direction the phenotype changes for each copy of the indicated allele.
3The p-values come from separate multivariate models for each locus that include all variants listed below, and the first five PCs. P-values shown here represent the
independent evidence for the specified variant, after conditioning on the array SNP.
4The percent variance in the phenotype accounted for by just the array SNP.
5The percent variance in the phenotype accounted for by the array SNP and the independent sequence variants.
doi:10.1371/journal.pgen.1004147.t002
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significance (p,561028) or the less stringent Bonferroni threshold
of .05/442= 1.161024.
Discussion
Large-scale re-sequencing has the potential to identify a
comprehensive set of variants that are missed by imputation and
chip based fine-mapping approaches. In more than 6,000
members of Finnish cohorts assessed for metabolic traits, we
re-sequenced 78 genes implicated in prior GWAS of these traits,
identifying 1,852 total variants, including .200 predicted-
deleterious missense variants and 23 nonsense variants, 125 of
which are not currently in the public database (dbSNP 137). Using
single-variant analyses, we found associations at seven loci (six
involving one or more variants with MAF,5%, Table 2) and
demonstrated using conditional analyses that these signals are
independent of previously reported GWAS SNPs. Using gene-level
tests we found compelling association evidence for rare variants in
two genes, ABCA1 and CETP. By comparison, Hunt et al. [26] in a
large (.40,00 individuals) autoimmune disease case-control
sample, found that targeted coding region re-sequencing of 25
GWAS risk genes provided minimal new information. Several
differences between our studies could account for the apparent
discrepancies in findings: First, the genetic architecture of
quantitative metabolic traits may be simpler than that of the
diseases investigated by Hunt et al. Second, we benefitted from the
effect of Finnish population history, which has led to a larger
proportion of variants in the Goldilocks allele range and a smaller
proportion of rare variants (about 70% of the variants observed by
Hunt et al. are present in one or two copies, compared to ,40% in
our study). Third, the genes for which we identify rare variant
associations may be unusual in their tolerance for functional
variation.
Our gene-level test results for ABCA1 agree with two previous
lines of evidence that rare variants in this gene could have an
impact on lipid phenotypes. First, recessive mutations in ABCA1
cause extreme reduction in HDL-C, termed Tangier Disease or
hypoalphalipoproteinemia; several of these variants were discov-
ered in Finnish families [27]. Second, previous studies in diverse
populations found enrichment of NS ABCA1 variants in individ-
uals with low HDL-C levels [21,28]. Among the fifteen previously
described rare NS variants observed in our data, ten have
previously been implicated in metabolic phenotypes: Tangier
Disease (n = 3), increased risk for heart disease (n = 2), or either
Figure 1. Schematic of rare (MAF,1%) non-synonymous variants used in the gene-level test of total cholesterol (TC) in gene ABCA1.
The x-axis scale (AA) is in amino acid positions. Numbers in parenthesis are the number of copies of the rare variant in persons with phenotype data.
The mean TC level in persons possessing variants with bold naming is increased relative to persons without the variant, for all other variants the
mean TC level in persons possessing variant alleles is decreased relative to persons without the variant.
doi:10.1371/journal.pgen.1004147.g001
Table 3. Rare and common variants contribute to the
association signal to HDL-C in gene ABCA1.
Variant MAF MAC Allele Type Beta P-value1
rs2575875 .30 4209 A array SNP 20.08 2.7E-04
rs2066718 .015 181 T missense
benign
0.32 1.0E-04
rs2066715 .055 674 T missense
benign
0.15 5.1E-04
Chr9:107548661 .00025 3 G missense
probably
damaging
22.08 2.9E-04
Chr9:107555091 .00049 6 C missense
benign
1.50 6.9E-04
Chr9:107555452 .00016 2 G missense
benign
22.94 2.8E-05
1P-values for rs2575875, rs2066718, and rs2066715 may be different from those
recorded in Table 2 because of the addition of the three rare variants to the
model. MAC: minor allele count.
doi:10.1371/journal.pgen.1004147.t003
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reduced (n= 3) or elevated (n= 2) serum HDL-C levels (Human
Gene Mutation Database).
Our results have enabled us to clarify genotype-phenotype
relationships for eight of the 17 loci examined. By delineating
multiple distinct association signals, and in some instances
highlighting specific candidate alleles, they also suggest potential
targets for functional investigations that could specify causal
variants. For example, at G6PC2 we identified a Goldilocks allele
at rs13872630 which has a predicted deleterious effect. This
variant has a distinct signal from the array SNP, and appears to
have a much stronger effect in lowering FG. As this effect may
provide protection against cardiovascular disease [29], there may
be great value in generating mice mutated for this His177Tyr
missense variant, which occurs at a highly conserved site.
Additionally, the relatively high frequency of this variant within
Finland offers an unusual opportunity to evaluate its impact on a
much wider range of phenotypes than we investigated here.
At the same time these findings also point to the difficulty in
predicting the phenotypic impact of individual variants. Recessive
mutations in several of the genes that we re-sequenced are
causative for rare metabolic disorders (e.g. [27]). However the
relatively modest effect on quantitative metabolic phenotypes that
we observed for variants in these and other genes predicted to be
deleterious (nonsense and missense) suggest two possibilities: 1) the
genetic and/or environmental backgrounds in families demon-
strating Mendelian metabolic disorders may differ from the
backgrounds in individuals drawn for population samples, and 2)
we must be cautious in assigning likely causality to variants on the
basis of annotation alone.
The incomplete coverage obtained for several loci provides an
additional reason for caution in our conclusions. Methods for
capturing a targeted region have become more efficient since we
completed our study, and therefore it is possible that implemen-
tation of such methods would provide more complete coverage at
these loci and could identify additional novel variants with a large
contributions to metabolic phenotypes.
Our prior hypothesis was that the process of genetic drift within
a recently expanded founder population such as Finland should
elevate the frequency of some deleterious alleles so that, even if
they are subject to strong selective pressure, they may be observed
at relatively high frequency [11]. In such populations, these
variants may be sufficiently common for phenotype-associations to
be detected using single-variant tests. As predicted by this
hypothesis, our re-sequencing identified, in G6PC2 and LIPC,
two missense variants predicted to be deleterious that are very rare
outside Finland (MAF,0.002), but that were sufficiently increased
in frequency (MAF.0.013) in our study sample for us to detect
significant association in single-variant tests. A recent genome-
wide survey of copy number variations has similarly demonstrated
that a rare deletion, highly over-represented within Finland, is
associated with neurodevelopmental disorders [30]. Taken
together, these results suggest that exome-wide and genome-wide
investigations of Finnish population cohorts will likely identify
Figure 2. Schematic of rare (MAF,1%) non-synonymous variants used in the gene-level test HDL-C in gene CETP. The x-axis scale (AA)
is in amino acid positions. Numbers in parenthesis are the number of copies of the rare variant in persons with phenotype data. The mean HDL-C
level in persons possessing variants with bold naming is increased relative to persons without the variant, for all other variants the mean HDL-C level
in persons possessing variant alleles is decreased relative to persons without the variant.
doi:10.1371/journal.pgen.1004147.g002
Table 4. Rare and common variants contribute to the
association signal to HDL-C in gene CETP.
Variant MAF MAC Allele Type Beta P-value1
rs3764261 .27 3913 A array SNP 0.28 1.6E-40
rs5883 .040 490 T coding-
synonymous
0.22 5.2E-06
rs5880 .024 296 C missense
probably
damaging
20.29 4.2E-05
rs2303790 .00057 7 G missense
possibly
damaging
1.31 1.0E-03
1P-values for rs3764261 and rs5880 may be different from those recorded in
Table 2 because of the addition of rs2303790 and rs5883 to the model. MAC:
minor allele count.
doi:10.1371/journal.pgen.1004147.t004
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additional associations to complex phenotypes that may not be
apparent in other populations.
Methods
Study samples
We obtained genomic DNA samples processed at the Finnish
Institute of Molecular Medicine (NFBC) and US National Human
Genome Research Institute (FUSION). All NFBC and FUSION
participants included in this study provided informed consent. The
studies were carried out in accordance with the approvals of the
Ethical Committee of the Northern Ostrobothnia Hospital District
(for NFBC), and the University of Michigan Health Sciences and
Behavioral Sciences Institutional Review Board (IRB-HSBS) and
the Institutional Review Board of the National Public Health
Institute (KTL; now part of the National Institute for Health and
Welfare, THL) (for FUSION).
Capture, sequencing, and quality control
We constructed Illumina multiplexed libraries with 5 mg of
whole genome amplified material (see Text S1 for description of
amplification procedures) or 1 mg native genomic DNA according
to the manufacturer’s protocol (Illumina Inc, San Diego, CA) with
the following modifications: 1) DNA was fragmented using a
Covaris E220 DNA Sonicator (Covaris, Inc. Woburn, MA) to
between 100 and 400 bp. 2) Illumina adapter-ligated library
fragments were amplified in four 50 mL PCR reactions for
eighteen cycles. 3) Solid Phase Reversible Immobilization bead
cleanup was used for enzymatic purification throughout the library
construction process and for final library size selection targeting
300–500 bp fragments. Samples were multiplexed using Illumina
barcoded libraries pooled together in pools of 12 or 18 depending
on the sequencing platform. We designed a custom targeted set of
150 bp probes (Agilent Technologies, Santa Clara, CA) and
captured ,270 kb of primarily coding sequence from 78 genes.
The concentration of each captured library pool was determined
through qPCR according to the manufacturer’s protocol (Kapa
Biosystems, Inc, Woburn, MA) to produce cluster counts
appropriate for the Illumina GAIIx and HiSeq 2000 platforms.
Sample pools of 12 and 18 were loaded on GAIIx and HiSeq
machines, respectively, using paired end 101 bp read lengths. We
aimed to achieve a coverage metric of 80% of the targeted space
covered at $206 depth. We aligned reads from each sample to
the NCBI37/hg19 reference sequence using BWA [31]. Sample
identity was confirmed by comparing sequence data (SAMtools
consensus calls) with pre-existing genotype array data. Individuals
with $70% coverage at 206 and $90% genotype concordance
with 51 array SNPs were included in the analysis (6,123 of 6,958
individuals).
Generation of consensus variant data set
Details on sequencing and generation of center-specific
genotype call sets can be found in Text S1. To generate a
consensus call set, we pooled together all quality controlled sites
discovered by any of the three centers (UCLA, University of
Michigan, or Washington University) in the defined target loci
(number of markers m=2,306). We excluded multi-allelic sites or
sites with different alternative alleles (m= 72). Each center then re-
called SNP genotypes at the remaining sites (m=2,234). Majority
vote was used to generate variant calls. Genotypes concordant
between at least two centers were included in the consensus data
set; others were set to missing. The overall concordance rate
between centers was 99.96% (99.99%, 99.94%, and 99.95% for
homozygous reference, heterozygous, and homozygous alternative
genotypes, respectively).
Principal components analysis (PCA)
NFBC individuals were previously genotyped on the Illumina
370duo Chip, and all FUSION cases and 774 of 919 FUSION
controls on the Illumina HumanHap300 BeadChip (version 1.0).
After standard quality control procedures [6,7], high-quality
GWAS genotypes were available for 296,978 SNPs for all
genotyped individuals. We used PLINK [32] to identify 122,644
SNPs with no more than moderate pair wise linkage disequilib-
rium (r2,0.5) which we used to calculate genetic principal
components (PCs) with EIGENSTRAT [33].
Association analysis
Phenotype transformation. We applied logarithm transfor-
mations to BMI, WHR, TG, glucose, insulin, and SBP to reduce
skewness. For each phenotype (or its logarithm), data from the two
studies combined were regressed on age, age2, and indicator
variables for sex, oral contraceptive use, pregnancy status, and
cohort, and residuals from this regression used in association
analyses. T2D cases were excluded from analysis of FG and FI.
Analyses were repeated using inverse normal transformed
variables, and our conclusions were robust to choice of transfor-
mation.
Single-variant analysis. We tested variants with minor
allele frequency (MAF).0.1% for association with phenotype
residuals in the combined NFBC/FUSION data set assuming an
additive genetic model and including the first five PCs as
covariates using PLINK [32]. We used conditional analyses to
determine if single-SNP associations were independent of geno-
types at the array SNP. Teslovich et al., in a previous GWAS meta-
analysis of lipid traits, identified, at several loci, associations
independent of their GWAS signals [8]. We sought to evaluate, at
all such GWAS loci highlighted by Teslovich et al., the correlation
between the signals identified through our conditional analyses
and the ‘‘independent’’ signals detected by Teslovich et al. We
could not make a direct comparison because at most loci the two
studies did not have data on the same sets of variants. We instead
used imputed data from Finnish reference populations to evaluate
pairwise LD between the variants from our study that we
compared with the variants from Teslovich et al. In this
comparison we considered any pair of variants with r2,0.20 to
be independent.
Gene-level tests. We conducted gene-level tests for pheno-
type residuals for each gene using non-synonymous variants with
MAF,1%. Only individuals with complete genotype data for all
variant sites were used in a given gene-level test of each gene;
sample size for gene-level tests ranged from 4,651 to 5,376
individuals. There were 62 genes with .1 non-synonymous
variant site with MAF,1%; the number of such sites ranged from
2 to 33 per gene.
We used the Combined Multivariate and Collapsing (CMC,
[22]) test that uses a weighted-sum-score-based linear model to test
the collective effect of multiple rare variants within a gene; see
Text S1 for more information on the form of the weighting
method used. We also employed the Sequence Kernel Association
Test (SKAT, [23]), which assumes that the effect sizes for
individual variants follow an arbitrary distribution with zero mean
and an unknown variance. SKAT uses a score-based variance
component approach to test the null hypothesis that the effect size
distribution has zero variance. For both CMC and SKAT, we
used the first five PCs as covariates.
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For SKAT, we used asymptotic theory p-values, which
conformed well to p-values estimated by permutation (data not
shown). For the CMC, we estimated p-values based on 10,000
permutations of the phenotype data. To estimate the p-value for
the ABCA1 association, we performed 1,000,000 permutations.
Significance thresholds. We employed FDR controlling
procedures [24] over the entire set of single-variant and gene-level
tests we conducted. Testing of each phenotype against variants/
genes in loci to which the phenotype had prior association resulted
in 2,096 tests (1,802 single-variant tests and 294 gene-level tests).
FDR control at the 0.05 level resulted in a p-value cut-off of 0.004,
and we opted to use a somewhat more stringent p-value threshold
of 0.001 corresponding to a FDR of 0.02.
Multivariate linear model selection. We used a standard
model selection approach to analyze the 39 locus-phenotype
combinations and derive the ‘‘best’’ multivariate linear model for
each phenotype based on all variants at the locus. We excluded
singletons from this analysis because the absence of any replication
in the study sample renders inference on their effect impossible
without making strong parametric assumptions. As a default model
selection approach, we used the Bayesian Information Criterion
(BIC) using a greedy search built into R (StepAIC). We again
included only complete observations in each locus-phenotype
combination. For each locus, the model with the smallest number
of predictor variables included the first five PCs, and the model
with the largest number of predictor variables included all non-
singleton variants genotyped.
Supporting Information
Figure S1 PC 1 and PC 2 from an analysis of GWAS data in
FUSION (red) and NFBC (black) samples. FUSION: circles are
individuals born in Lapland, crosses are individuals born in Oulu,
triangles are individuals born elsewhere in Finland. NFBC: the
birthplace of both parents of NFBC subjects are indicated by
different symbols, in the legend the slash separates the location of
birth of each parent. Lap=Lapland.
(PDF)
Figure S2 Summary of coverage by person and gene. A: Person-
specific average depth of coverage over all the targeted genes. 107
persons with mean coverage .5006were omitted to improve plot
clarity. B: Gene-specific average coverage depth across all subjects
and all targeted basepairs within each gene. C: Relationship
between the percent of target basepairs in a gene and GC content.
HighGC=mean GC in a gene .60%; LowGC=mean GC in a
gene ,=60%.
(PDF)
Figure S3 Distribution of variant types and targeted sequence
regions. Top: proportion of variant sites (left) and sequenced
basepairs (right) that are intronic, utr, coding (synonymous,
missense and nonsense). The purple and yellow hatched region
indicates coding basepairs. Bottom: proportion of variant site types
by minor allele frequency category.
(PDF)
Figure S4 Boxplots of raw phenotypic values vs. the number of
alternative alleles at deleterious variant sites. Deleterious sites are
nonsense and missense variants predicted to be probably
deleterious by PolyPhen-2. In the title, the number in parentheses
is the number of persons homozygous for the alternative allele at
the variant site.
(PDF)
Figure S5 Summary of variant allele frequency. A: Site
frequency spectrum. On the y axis is the proportion of variant
sites with a specified minor allele count. On the x axis are minor
allele counts running from 1 (singleton sites) to 20. Data were
down-sampled to a common sample size of 6,000 persons using
the hypergeometic distribution. B: Relationship between minor
allele frequency (MAF) and presence of variant in dbSNP 137.
(PDF)
Figure S6 Regions and phenotypes where significant association
with single SNP analysis of SNPs with MAF.0.11% was
independent of the array SNP association. For each phenotype-
region combination two plots are presented, single-SNP associa-
tion, and single-SNP association conditional on the array SNP (in
purple, and labeled with text). Color scale is LD relative to the
array SNP. On the y-axis is the 2log10(P-value) for association to
the indicated phenotype, on the x-axis is position in Mb from
hg19. Up triangles: nonsense variants; down triangles: missense
variants; squares: synonymous and utr variants; circles: no
annotation available. The loci are named according to the first
gene in the region of interest, starting at the 59 end of the region.
A. LDL-C in ABCG8 locus B. LDL-C in ABCG8 locus, conditional
analysis C. FG in G6PC2 locus D. FG in G6PC2 locus, conditional
analysis E. HDL-C in LPL locus F. HDL-C in LPL locus,
conditional analysis G. TG in LPL locus H. TG in LPL locus,
conditional analysis I. HDL-C in ABCA1 locus J. HDL-C in
ABCA1 locus, conditional analysis K. TG in APOA1 locus L. TG in
APOA1 locus, conditional analysis M. LDL-C in APOA1 locus N.
LDL-C in APOA1 locus, conditional analysis O. TC in APOA1
locus P. TC in APOA1 locus, conditional analysis Q. TG in LIPC
locus R. TG in LIPC locus, conditional analysis S. HDL-C in LIPC
locus T. HDL-C in LIPC locus, conditional analysis U. HDL-C in
CETP locus V. HDL-C in CETP locus, conditional analysis.
(PDF)
Table S1 Comparison of phenotypic values for NFBC partic-
ipants and FUSION cases and controls.
(XLS)
Table S2 Description of the 78 genes sequenced.
(XLS)
Table S3 All 1,852 variants analyzed in the study. SNPs not
found in dbSNP137 are named by the chromosome and position.
Phenotype abbreviations are as in Table S1.
(XLS)
Table S4 Percent of variants in coding regions with MAF,1%
in various studies. All comparisons involve persons of European
ancestry.
(DOCX)
Table S5 Results of all gene-level tests of rare variants in genes
that are found in regions of a priori association to the indicated
phenotype.
(XLS)
Text S1 Supplementary methods.
(DOC)
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